NGL Fine Chem Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹159 Cr +32.5% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
NF

NGL Fine Chem Ltd

Q1 FY27Pharmaceuticals & Biotechnology

NGL Fine Chem Q1 FY27: Revenue ₹139.16 Cr, PAT ₹18.40 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹139Cr
+33.7% YoY
−6.7% QoQ
Net profit
₹18Cr
+100% YoY
+38.5% QoQ
Margin
17%
+6 pp YoY
+3 pp QoQ

Based on NGL Fine Chem Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹2,895
Market cap₹1.7K Cr
P/E33.9

The short version

Quarterly Revenue (Q1FY27): ₹139.16 crores. EBITDA for Q1FY27: ₹23.29 crores, up 112.21% YoY.

From NGL Fine Chem Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Quarterly Revenue (Q1FY27): ₹139.16 crores
  • Year-on-Year (YoY) growth: 33.57%
  • Revenue from Operations: ₹139.16 crores in Q1FY27 (vs. ₹104.19 crores in Q1FY26)
  • Other Income: ₹7.43 crores in Q1FY27, up 16.91% YoY
  • Total Income: ₹146.59 crores in Q1FY27, up 32.61% YoY
  • Volume Outlook: Management commentary states sustained demand momentum with volumes remaining robust across product segments and geographies.

2 more points from NGL Fine Chem Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Greenfield expansion at Tarapur:
  • A larger expansion to drive the next leg of exponential growth.
  • Estimated capex of ₹210 crore.
  • Funded through debt and internal accrual.
  • Civil construction underway, with ₹209.71 crore invested till Q1FY27.
  • Commercial production expected to start from H2FY27.
  • Phase II Capex:
  • On schedule for commissioning during the current quarter (Q1FY27).
  • Total project cost and scope remain unchanged.
  • Expected to commence commercial production from H2FY27.
  • Incremental capacity to support growth plans and new market opportunities.
  • Completed expansion in subsidiary Macrotech:

2 more points from NGL Fine Chem Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what NGL Fine Chem Ltd said on order book & pipeline — free account, 30 seconds.

NGL Fine Chem Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

NGL Fine Chem Ltd Q1 FY27 results — key figures

NGL Fine Chem Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue139104+33.7%149-6.7%
Operating profit (EBITDA)2311+109.1%21+9.5%
Operating margin17%11%+6 pp14%+3 pp
Profit before tax2412+100%18+33.3%
Net profit (PAT)189+100%13+38.5%
EPS (₹)29.7814.96+99.1%21.84+36.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹159 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

NGL Fine Chem Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were NGL Fine Chem Ltd Q1 FY27 results?

Quarterly Revenue (Q1FY27): ₹139.16 crores. EBITDA for Q1FY27: ₹23.29 crores, up 112.21% YoY.

What is NGL Fine Chem Ltd share price analysis?

NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.

Is NGL Fine Chem Ltd planning capital expenditure?

Greenfield expansion at Tarapur: - A larger expansion to drive the next leg of exponential growth.

Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.